UBS Group
MAZE

UBS Group’s Maze Therapeutics MAZE Stock Holding History

UBS Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
84,679
-9,219
-10% -$242K ﹤0.01% 4892
2026
Q1 		$2.8M Buy
93,898
+65,200
+227% +$2.88M ﹤0.01% 4654
2025
Q4 		$1.19M Buy
28,698
+905
+3% +$31.1K ﹤0.01% 5430
2025
Q3 		$721K Sell
27,793
-23,609
-46% -$399K ﹤0.01% 5821
2025
Q2 		$631K Sell
51,402
-36,662
-42% -$381K ﹤0.01% 5825
2025
Q1 		$970K Buy
+88,064
New +$1.06M ﹤0.01% 5305

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

UBS Group's MAZE Position: Q2 2026 in Review

UBS Group reduced its Maze Therapeutics (MAZE) stake by 9.8% in Q2 2026, selling an estimated $242K and leaving 84,679 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #4892.

UBS Group first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.8M in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • UBS Group held 84,679 shares of Maze Therapeutics worth $2.53M as of Q2 2026.
  • UBS Group sold 9,219 Maze Therapeutics shares in Q2 2026, an estimated $242K.
  • Maze Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4892 holding.
  • UBS Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Maze Therapeutics position peaked at $2.8M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.